z-logo
open-access-imgOpen Access
The Association between Serological Biomarkers and Primary Sjogren’s Syndrome Associated with Peripheral Polyneuropathy
Author(s) -
Che-Wei Hsu,
YuJih Su,
WenNeng Chang,
NaiWen Tsai,
WenChan Chiu,
BenChung Cheng,
Chih-Min Su,
Chi-Ren Huang,
YaTing Chang,
ChengHsien Lu
Publication year - 2014
Publication title -
biomed research international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 126
eISSN - 2314-6141
pISSN - 2314-6133
DOI - 10.1155/2014/902492
Subject(s) - autoantibody , medicine , serology , peripheral neuropathy , polyneuropathy , biomarker , peripheral , gastroenterology , pathology , antibody , immunology , endocrinology , diabetes mellitus , biology , biochemistry
Background and Aim . The sensitivity and specificity of biomarkers used for predicting peripheral neuropathy of Sjogren's syndrome (SJS) patients remain unsatisfactory. This study aimed to determine the prognostic value of circulating autoantibodies levels in SJS patients with peripheral neuropathy. Methods . Two hundred and fifty serological positive (either anti-Ro or anti-La positive) SJS patients' data were collected retrospectively. The titers of autoantibodies, electrophysiology reports, and clinical manifestation were reviewed. Results . The prevalence rate of peripheral neuropathy is 7.2% in our study. Regarding classification of peripheral neuropathy, 12 had mixed sensorimotor polyneuropathy, six had cranial neuropathy. After stepwise logistic regression analysis, anti- β 2 glycoprotein I (a β 2GP I) and perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) were significantly associated with peripheral neuropathy in serology positive SJS ( P = 0.01, P = 0.046, resp.). Conclusion . The occurrence of peripheral neuropathy among SJS patients is not frequent and easily overlooked. Our study demonstrated that a β 2GP I and p-ANCA levels may imply the danger of the occurrence of neuropathy in SJS patients, and they can be considered a biomarker that should be added to the panel of conventional autoantibody in SJS patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom